Inlay

Same as we reached within #PANCAIM @euprojectpulse.bsky.social project with the #grandchallenge #PANORAMA study! Read our piece in @thelancet.com

ICYMI: New online! Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice

In this issue of Developmental Cell, Wang et al. establish a murine resectable pancreatic ductal adenocarcinoma (PDAC) model and identify circadian re…

🔎 Know the Symptoms of Pancreatic Cancer Recently diagnosed with diabetes and not sure why? In some cases, new-onset diabetes can be linked to pancreatic cancer. Learn the 10 warning signs: https://pancreaticcancereurope.eu/wp-content/uploads/2024/04/10WS_en.pdf

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://nej.md/4fKYQG4 #EULAR2026

Morgen startet die Aktionswoche Alkohol - unterstützt durch die Stabsstelle #Krebsprävention des DKFZ. Sie lädt dazu ein, sich mit #Alkohol und Alkoholkonsum kritisch auseinanderzusetzen. Hier gibt es wissenschaftlich fundierte Informationsmaterialien: t1p.de/80guf @bdb-offiziell.bsky.social

Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://bit.ly/4uWZ9C5 #OncSky

Did you know Gutflix has bookmarks? 🔖 Build your 'study later' list 🔖 Pick up where you left off 🔖 Save what matters to your practice Bookmark your favourite content today: https://gutflix.eu/

Screening can help reverse the rising trend of digestive cancers across Europe – but only if it reaches everyone. Zorana Maravic from @digestivecancerseu.bsky.social calls for urgent action to raise awareness, increase uptake & close the access gap: https://bit.ly/4mYFleR #DigestiveHealthMonth

Nature Reviews Gastroenterology & Hepatology, Published online: 20 May 2026; doi:10.1038/s41575-026-01214-8Metabolic dysfunction-associated steatotic liver disease is a leading cause of chronic liver disease, with rising liver transplantation rates. New therapies such as resmetirom and semaglutide mark a shift in treatment. However, identifying suitable patients remains challenging, requiring integrated approaches combining fibrosis stage, metabolic factors and non-invasive tools in real-world practice.